Efficacy in Patients with Portal-Systemic Encephalopathy treated via Balloon-occluded Retrograde Transvernous Obliteration

Efficacy in Patients with Portal-Systemic Encephalopathy treated via Balloon-occluded Retrograde Transvernous Obliteration - Efficacy in patients with Portal-Systemic Encephalopathy treated via B-RTO

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000943

Enrollment

Registered

2008-10-01

Start date

2003-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients with portal-systemic encephalopathy, and presence of gastro-renal shunts(above 1cm in a diameter), as determined via contrast enhanced computed tomography (CT)

Interventions

B-RTO standard therapy(drug)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.The presence of gastrorenal shunts, (above 1 cm in a diameter), as determined via contrast enhanced computed tomography 2.Liver cirrhosis with hepatic encehalopathy

Exclusion criteria

Exclusion criteria: 1.recent gastrointestinal bleeding 2.Child-Pugh classification C 3.serum creatinine level>2 mg/dl 4. HCC 5.splenectomy,PSE,TIPS, and Hassab operation 6.portal vein thrombosis

Design outcomes

Primary

Measure	Time frame
Neuropsychological Tests improvement of hepatic encephalopathy	—

Secondary

Measure	Time frame
1.Event(death,gastrointestinal bleeding,occurrence of HCC, and liver failure) 2.Child-Pugh score, and MELD 3.Serum laboratory values included the serum ammonia level 4.HQOL(SF-36)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026